Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 6, 2007 - Issue 2
Submit an article Journal homepage
317
Views
25
CrossRef citations to date
0
Altmetric
Review

Incidence and management of cutaneous toxicities associated with cetuximab

M Wasif Saif Associate Professor, Yale University School of Medicine, Division of Medical Oncology, 333 Cedar Street, FMP 116, New Haven, CT 06520, USA . [email protected]
&
Richard Kim Cleveland Clinic Taussig Cancer Center, Department of Solid Tumor Oncology, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Pages 175-182 | Published online: 16 Mar 2007

Citations (25)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Yariv Mazor, Vaheh Oganesyan, Chunning Yang, Anna Hansen, Jihong Wang, Hongji Liu, Kris Sachsenmeier, Marcia Carlson, Dhanesh V Gadre, Martin Jack Borrok, Xiang-Qing Yu, William Dall’Acqua, Herren Wu & Partha Sarathi Chowdhury. (2015) Improving target cell specificity using a novel monovalent bispecific IgG design. mAbs 7:2, pages 377-389.
Read now
Charu Aggarwal & Hossein Borghaei. (2009) Rational use of cetuximab in the treatment of advanced non-small cell lung cancer. OncoTargets and Therapy 2, pages 251-260.
Read now
Melarkode S. Ramakrishnan, Anand Eswaraiah, Tania Crombet, Patricia Piedra, Giselle Saurez, Harish Iyer & A.S. Arvind. (2009) Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. mAbs 1:1, pages 41-48.
Read now
Sanjay R Hegde, Weijing Sun & John P Lynch. (2008) Systemic and targeted therapy for advanced colon cancer. Expert Review of Gastroenterology & Hepatology 2:1, pages 135-149.
Read now
Foluso O Ademuyiwa & Nasser Hanna. (2008) Cetuximab in non-small cell lung cancer. Expert Opinion on Biological Therapy 8:1, pages 107-113.
Read now

Articles from other publishers (20)

Diva Silva, Ana Gomes, José MS Lobo, Vera Almeida & Isabel F Almeida. (2020) Management of skin adverse reactions in oncology. Journal of Oncology Pharmacy Practice 26:7, pages 1703-1714.
Crossref
Leslie Pérez Ruiz, Manuel M. Collazo Herrera, Normando Iznaga Escobar & Carmen E. Viada González. (2016) Evaluación económica del tratamiento con nimotuzumab para el cáncer de cabeza y cuello en Cuba. PharmacoEconomics Spanish Research Articles 13:4, pages 133-140.
Crossref
Christian Rolfo, Giuseppe Bronte, Francesco Passiglia, Konstantinos Papadimitriou, Antonio Russo & Marc Peeters. (2013) Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer. Current Colorectal Cancer Reports 9:3, pages 250-260.
Crossref
Janja Ocvirk, Steffen Heeger, Philip McCloud & Ralf-Dieter Hofheinz. (2013) A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a metaanalysis. Radiology and Oncology 47:2, pages 166-175.
Crossref
Yüksel ÜrünGüngör Utkan. (2013) Cetuximab Related Eyelash Elongations for Patients with Metastatic Rectum Carcinoma: Metabolic Complete Response. Annals of Dermatology 25:4, pages 504.
Crossref
Pia Vihinen, Outi Paija, Atte Kivisaari, Leena Koulu & Heikki Aho. (2011) Cutaneous lupus erythematosus after treatment with paclitaxel and bevacizumab for metastatic breast cancer: a case report. Journal of Medical Case Reports 5:1.
Crossref
Albert Mas-Vidal, Pablo Coto-Segura, Cristina Galache-Osuna & Jorge Santos-Juanes. (2011) Psoriasis induced by cetuximab: A paradoxical adverse effect. Australasian Journal of Dermatology 52:1, pages 56-58.
Crossref
James E. Frampton. (2010) Cetuximab. Drugs 70:15, pages 1987-2010.
Crossref
Federico Rojo, Elías Gracias, Nadia Villena, Teresa Cruz, Josep Maria Corominas, Irene Corradino, Mercedes Cedeño, Clara Campas, Marta Osorio, Normando Iznaga, Beatriz Bellosillo, Ana Rovira, Silvia Marsoni, Pere Gascon, Sergio Serrano, Cristiana Sessa, Tania Crombet & Joan Albanell. (2010) Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study. Clinical Cancer Research 16:8, pages 2474-2482.
Crossref
S. M. Breathnach. 2010. Rook's Textbook of Dermatology. Rook's Textbook of Dermatology 1 177 .
Jeffrey B Hoag, Aimel Azizi, Timothy J Doherty, Jason Lu, Rudolph E Willis & Mark E Lund. (2009) Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review. Journal of Experimental & Clinical Cancer Research 28:1.
Crossref
Marc Pallardy. (2009) Les complications « toxiques » liées à l’utilisation des anticorps monoclonaux. médecine/sciences 25:12, pages 1130-1134.
Crossref
Ariel Talavera, Rosmarie Friemann, Silvia Gómez-Puerta, Carlos Martinez-Fleites, Greta Garrido, Ailem Rabasa, Alejandro López-Requena, Amaury Pupo, Rune F. Johansen, Oliberto Sánchez, Ute Krengel & Ernesto Moreno. (2009) Nimotuzumab, an Antitumor Antibody that Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding while Permitting the Active Receptor Conformation. Cancer Research 69:14, pages 5851-5859.
Crossref
Muhammad Wasif Saif, J. Peccerillo & Von Potter. (2008) Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature. Cancer Chemotherapy and Pharmacology 63:6, pages 1017-1022.
Crossref
Patricia L. Myskowski & Allan C. Halpern. (2009) Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer. Current Colorectal Cancer Reports 5:2, pages 120-125.
Crossref
Mohammad A. Tabrizi, Gadi Gazit Bornstein, Scott L. Klakamp, Andrew Drake, Richard Knight & Lorin Roskos. (2009) Translational strategies for development of monoclonal antibodies from discovery to the clinic. Drug Discovery Today 14:5-6, pages 298-305.
Crossref
M. Wasif Saif, Walter L. Longo & Gary Israel. (2008) Correlation Between Rash and a Positive Drug Response Associated with Bevacizumab in a Patient with Advanced Colorectal Cancer. Clinical Colorectal Cancer 7:2, pages 144-148.
Crossref
Jae Woo ParkSun-Mi MoonDae-Yong Hwang. (2008) Retrospective Analysis of Patients Treated with Cetuximab plus FOLFIRI for Previous Irinotecan-combined Chemotherapy in Metastatic Colorectal Cancer. Journal of the Korean Society of Coloproctology 24:5, pages 345.
Crossref
Patricia L. Myskowski & Allan C. Halpern. (2008) Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer. Current Allergy and Asthma Reports 8:1, pages 63-68.
Crossref
Stephanie K A Blick & Lesley J Scott. (2007) Cetuximab. Drugs 67:17, pages 2585-2607.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.